Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P35052
UPID:
GPC1_HUMAN
Alternative names:
-
Alternative UPACC:
P35052; B3KTD1; Q53QM4
Background:
Glypican-1, encoded by the gene P35052, is a cell surface proteoglycan with heparan sulfate side chains. It plays a crucial role in various biological processes, including Schwann cell myelination, prion protein conversion, and skeletal muscle differentiation. By binding alpha-4 (V) collagen and sequestering FGF2, Glypican-1 influences cell signaling and tissue development.
Therapeutic significance:
Understanding the role of Glypican-1 could open doors to potential therapeutic strategies. Its involvement in key biological processes suggests that modulating its activity could offer new avenues for treating diseases related to myelination, prion infections, and muscle differentiation disorders.